Suprane is a drug owned by Baxter Healthcare Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2014. Details of Suprane's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5617906 (Pediatric) | Container for anaesthetic agent |
Oct, 2014
(10 years ago) |
Expired
|
| US5617906 | Container for anaesthetic agent |
Apr, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Suprane is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Suprane's family patents as well as insights into ongoing legal events on those patents.
Suprane's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Suprane's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 08, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Suprane Generic API suppliers:
Desflurane is the generic name for the brand Suprane. 1 company has already filed for the generic of Suprane. Check out the entire list of companies who have already received approval for Suprane's generic
How can I launch a generic of Suprane before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Suprane's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Suprane's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Suprane -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.999 | 11 Sep, 2008 | 1 | 08 Apr, 2014 | Extinguished |
About Suprane
Suprane is a drug owned by Baxter Healthcare Corp. Suprane uses Desflurane as an active ingredient. Suprane was launched by Baxter Hlthcare in 1992.
Approval Date:
Suprane was approved by FDA for market use on 18 September, 1992.
Active Ingredient:
Suprane uses Desflurane as the active ingredient. Check out other Drugs and Companies using Desflurane ingredient
Dosage:
Suprane is available in liquid form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100% | LIQUID | Prescription | INHALATION |